Lung microbiome composition and bronchial epithelial gene expression in patients with COPD versus healthy individuals: a bacterial 16S rRNA gene sequencing and host transcriptomic analysis
- PMID: 35544166
- DOI: 10.1016/S2666-5247(21)00035-5
Lung microbiome composition and bronchial epithelial gene expression in patients with COPD versus healthy individuals: a bacterial 16S rRNA gene sequencing and host transcriptomic analysis
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is associated with airway inflammation and bacterial dysbiosis. The relationship between the airway microbiome and bronchial gene expression in COPD is poorly understood. We aimed to identify differences in the airway microbiome from bronchial brushings in patients with COPD and healthy individuals and to investigate whether any distinguishing bacteria are related to bronchial gene expression.
Methods: For this 16S rRNA gene sequencing and host transcriptomic analysis, individuals aged 45-75 years with mild-to-moderate COPD either receiving or not receiving inhaled corticosteroids and healthy individuals in the same age group were recruited as part of the Emphysema versus Airways Disease (EvA) consortium from nine centres in the UK, Germany, Italy, Poland, and Hungary. Individuals underwent clinical characterisation, spirometry, CT scans, and bronchoscopy. From bronchoscopic bronchial brush samples, we obtained the microbial profiles using 16S rRNA gene sequencing and gene expression using the RNA-Seq technique. We analysed bacterial genera relative abundance and the associations between genus abundance and clinical characteristics or between genus abundance and host lung transcriptional signals in patients with COPD versus healthy individuals, and in patients with COPD with versus without inhaled corticosteroids treatment.
Findings: Between February, 2009, and March, 2012, we obtained brush samples from 574 individuals. We used 546 of 574 samples for analysis, including 207 from healthy individuals and 339 from patients with COPD (192 with inhaled corticosteroids and 147 without). The bacterial genera that most strongly distinguished patients with COPD from healthy individuals were Prevotella (median relative abundance 33·5%, IQR 14·5-49·4, in patients with COPD vs 47·7%, 31·1-60·7, in healthy individuals; p<0·0001), Streptococcus (8·6%, 3·8-15·8, vs 5·3%, 3·0-10·1; p<0·0001), and Moraxella (0·05%, 0·02-0·14, vs 0·02%, 0-0·07; p<0·0001). Prevotella abundance was inversely related to COPD severity in terms of symptoms and positively related to lung function and exercise capacity. 446 samples had assessable RNA-seq data, 257 from patients with COPD (136 with inhaled corticosteroids and 121 without) and 189 from healthy individuals. No significant associations were observed between lung transcriptional signals from bronchial brushings and abundance of bacterial genera in patients with COPD without inhaled corticosteroids treatment and in healthy individuals. In patients with COPD treated with inhaled corticosteroids, Prevotella abundance was positively associated with expression of epithelial genes involved in tight junction promotion and Moraxella abundance was associated with expression of the IL-17 and TNF inflammatory pathways.
Interpretation: With increasing severity of COPD, the airway microbiome is associated with decreased abundance of Prevotella and increased abundance of Moraxella in concert with downregulation of genes promoting epithelial defence and upregulation of pro-inflammatory genes associated with inhaled corticosteroids use. Our work provides further insight in understanding the relationship between microbiome alteration and host inflammatory response, which might lead to novel therapeutic strategies for COPD.
Funding: EU Seventh Framework Programme, National Institute for Health Research.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of interests CEB reports grants from EvA Seventh Framework Programme (FP7), Airway Disease Predicting Outcomes through Patient Specific Computational Modelling (AirPROM) FP7, and UK National Institute for Health Research (NIHR), during the conduct of the study, and grants and personal fees from AstraZeneca, GlaxoSmithKline, Novartis, Chiesi, Mologic, 4DPharma, and Genentech; and personal fees from Sanofi and Regeneron, outside the submitted work. TW reports grants from the EU (#200506) and the German Ministry of Research and Education, during the conduct of the study. TG reports grants from the EU, during the conduct of the study, and personal fees from AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, and CSL Behring; grants and personal fees from Grifols; and grants from the German Centre for Lung Research, outside the submitted work. LZ-H reports grants from the European Commission, during the conduct of the study. JMH reports grants from EU FP7, during the conduct of the study, and personal fees from Boehringer Ingelheim, Merck, Novartis, and HAL; and grants from AstraZeneca, Novartis, Janssen Pharmaceutica, ALK, Boehringer Ingelheim, LETI Pharma, GlaxoSmithKline, Sanofi-Aventis, Astellas Pharma, and Allergopharma, outside the submitted work. IG reports grants from the European Commission, during the conduct of the study. IB reports grants from EU FP7, during the conduct of the study. DGP reports personal fees from Mereo BioPharma, and CSL Behring, outside the submitted work. DS reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Genentech, GlaxoSmithKline, Glenmark, Menarini, Mundipharma, Novartis, Peptinnovate, Pfizer, Pulmatrix, Theravance, and Verona, outside the submitted work. All other authors declare no competing interests.
Similar articles
-
Airway host-microbiome interactions in chronic obstructive pulmonary disease.Respir Res. 2019 Jun 6;20(1):113. doi: 10.1186/s12931-019-1085-z. Respir Res. 2019. PMID: 31170986 Free PMC article.
-
Influence of lung CT changes in chronic obstructive pulmonary disease (COPD) on the human lung microbiome.PLoS One. 2017 Jul 13;12(7):e0180859. doi: 10.1371/journal.pone.0180859. eCollection 2017. PLoS One. 2017. PMID: 28704452 Free PMC article.
-
Bacterial biogeography of adult airways in atopic asthma.Microbiome. 2018 Jun 9;6(1):104. doi: 10.1186/s40168-018-0487-3. Microbiome. 2018. PMID: 29885665 Free PMC article.
-
The alterations of oral, airway and intestine microbiota in chronic obstructive pulmonary disease: a systematic review and meta-analysis.Front Immunol. 2024 May 8;15:1407439. doi: 10.3389/fimmu.2024.1407439. eCollection 2024. Front Immunol. 2024. PMID: 38779669 Free PMC article.
-
Sputum microbiome profiling in COPD: beyond singular pathogen detection.Thorax. 2020 Apr;75(4):338-344. doi: 10.1136/thoraxjnl-2019-214168. Epub 2020 Jan 29. Thorax. 2020. PMID: 31996401 Free PMC article. Review.
Cited by
-
Exploring the Role of Gut-Lung Interactions in COPD Pathogenesis: A Comprehensive Review on Microbiota Characteristics and Inflammation Modulation.Chronic Obstr Pulm Dis. 2024 May 29;11(3):311-325. doi: 10.15326/jcopdf.2023.0442. Chronic Obstr Pulm Dis. 2024. PMID: 38563747 Free PMC article.
-
Characterization of the gut microbiota in drug abuse: prediction, prevention, and personalized medicine to benefit affected populations.EPMA J. 2025 Mar 15;16(2):505-517. doi: 10.1007/s13167-025-00402-x. eCollection 2025 Jun. EPMA J. 2025. PMID: 40438492 Review.
-
Combining p-values from various statistical methods for microbiome data.Front Microbiol. 2022 Nov 10;13:990870. doi: 10.3389/fmicb.2022.990870. eCollection 2022. Front Microbiol. 2022. PMID: 36439799 Free PMC article.
-
Insights into the role of the respiratory tract microbiome in defense against bacterial pneumonia.Curr Opin Microbiol. 2024 Feb;77:102428. doi: 10.1016/j.mib.2024.102428. Epub 2024 Jan 25. Curr Opin Microbiol. 2024. PMID: 38277901 Free PMC article. Review.
-
Interactions between the lung microbiome and host immunity in chronic obstructive pulmonary disease.Chronic Dis Transl Med. 2023 Apr 3;9(2):104-121. doi: 10.1002/cdt3.66. eCollection 2023 Jun. Chronic Dis Transl Med. 2023. PMID: 37305112 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical